eular2haq: HAQ change by 6-month EULAR Response

Description Usage Format Source

Description

Mean and standard deviation of HAQ change by 6-month EULAR response category (none, moderate, good).

Usage

1

Format

A matrix with rows as EULAR response categories. First column is mean and second column is standard deviation.

Source

Stevenson, Matt, et al. "Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation." Health Technology Assessment 20.35 (2016): 1-610.


InnovationValueInitiative/IVI-RA documentation built on Oct. 20, 2020, 10:02 p.m.